**Supplementary table 1**. Logistic regression model performed to create the propensity score.

|  |  |  |
| --- | --- | --- |
|  | **OR (95% CI)** | **P value** |
| Age, years | 1.02 (0.99-1.06) | 0.112 |
| Male gender  | 1.68 (0.82-3.42) | 0.155 |
| Penetrating behavior | 0.74 (0.34-1.60) | 0.444 |
| Perianal disease prior to surgery | 1.76 (0.71-4.33) | 0.221 |
| Extra-intestinal manifestations | 0.85 (0.31-1.87) | 0.679 |
| Active smokers at index surgery | 0.96 (0.69-1.34) | 0.814 |
| Previous intestinal resections | 0.90 (0.34-2.33) | 0.821 |
| Anti-TNF exposure prior to the index surgery | 0.69 (0.33-1.45) | 0.325 |
| At least 1 risk factor for POR | 1.09 (0.42-2.85) | 0.859 |
| Clinical POR at anti-TNF start | 0.98 (0.45-2.14) | 0.962 |
| Time from index surgery to anti-TNF start | 1.00 (1.00-1.01) | 0.466 |
| Time from Crohn’s disease diagnosis to index surgery | 1.00 (0.99-1.00) | 0.873 |
| Median (IQR) follow-up time on anti-TNF (*months*) | 1.01 (1.00-1.02) | 0.013 |
| Advanced endoscopic POR | 0.82 (0.42-1.60) | 0.555 |
| Postoperative prevention with thiopurines | 1.51 (0.75-3.05) | 0.253 |
| Concomitant thiopurines | 1.47 (0.70-3.10) | 0.308 |

**Supplementary table 2.** Baseline characteristics of patients in the propensity-score matching cohort.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Infliximab****(n=63)** | **Adalimumab****(n=63)** | **p value** |
| Male gender  | 35 (56) | 32 (51) | 0.59 |
| Familial with inflammatory bowel disease | 7 (11) | 6 (10) | 0.77 |
| Active smoking at Crohn’s disease diagnosis | 36 (57) | 35 (56) | 0.86 |
| Disease location Ileal  Ileocolonic Upper gastrointestinal involvement | 37 (59)26 (41)1 (2) | 36 (57)24 (38)3 (5) | 0.860.720.31 |
|  Disease behavior Inflammatory Stricturing Penetrating | 3 (5)30 (48)30 (48) | 4 (6)30 (48)29 (46) | 0.701.000.86 |
| Extra-intestinal manifestations Rheumatologic Cutaneous Ocular Thrombotic | 17 (27)14 (22)4 (6)4 (6)1 (2) | 15 (24)13 (21)3 (5)1 (2)0 | 0.680.830.500.180.50 |
| Age group at diagnosis <18 years 18-40 years >40 years | 7 (11)47 (75)9 (14) | 9 (14)46 (68)11 (17) | 0.590.430.62 |
| Indication of index surgery Intestinal stenosis Intraabdominal penetrating  complication Refractoriness to medical  therapy | 37 (59)20 (32)6 (10) | 32 (51)25 (40)6 (10) | 0.370.351.00 |
| Thiopurines exposure prior to index surgery | 41 (65) | 34 (54) | 0.20 |
| Anti-TNF exposure prior to index surgery | 19 (30) | 16 (25)  | 0.55 |
| Active smoking at index surgery | 31 (49) | 31 (49) | 1.00 |
| Penetrating behavior  | 30 (48)  | 29 (46) | 0.85 |
| Perianal disease before index surgery | 9 (14) | 10 (16) | 0.80 |
| Intestinal resections prior to index surgery | 8 (13) | 13 (21) | 0.23 |
| At least 1 risk factor for POR>1 known risk factor for POR | 48 (76)22 (35) | 50 (79)25 (39) | 0.690.58 |
| Time from index surgery to index ileocolonoscopy (*months*) | 16 (7-46) | 15 (7-47) | 0.99 |
| Rutgeerts score at the beginning of anti-TNF Rutgeerts i2 Rutgeerts i3 Rutgeerts i4 | 26 (41)17 (27)20 (32) | 27 (43)15 (24)21 (33) | 0.860.680.85 |
| Median time (IQR) from surgery to anti-TNF (*months*) | 40 (20-74) | 37 (12-78) | 0.37 |
| Clinical POR at anti-TNF start | 14 (22) | 15 (24) | 0.83 |
| Anti-TNF induction schedule  | 62 (98) | 62 (98) | 1.00 |
| Concomitant immunosuppressants Thiopurines  Methotrexate | 44 (70)6 (9) | 43 (68)1 (2) | 0.850.06 |
| C-reactive protein >5 mg/L | 16 (30) | 20 (32) | 0.85 |
| Hemoglobin < 12 g/dL (men) or <11 g/dL (women)  | 7 (11) | 8 (13) | 0.78 |